{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?hansardHeading=Clinical+Trials&max-answer.questionFirstAnswered.=2024-01-11T15%3A39%3A08.697Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?hansardHeading=Clinical+Trials&max-answer.questionFirstAnswered.=2024-01-11T15%3A39%3A08.697Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_metadata=all&hansardHeading=Clinical+Trials&max-answer.questionFirstAnswered.=2024-01-11T15%3A39%3A08.697Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&hansardHeading=Clinical+Trials&max-answer.questionFirstAnswered.=2024-01-11T15%3A39%3A08.697Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?hansardHeading=Clinical+Trials&max-answer.questionFirstAnswered.=2024-01-11T15%3A39%3A08.697Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?hansardHeading=Clinical+Trials&max-answer.questionFirstAnswered.=2024-01-11T15%3A39%3A08.697Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1672225", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1672225/answer", "answerText" : {"_value" : "<p>The Vision for the Future of UK Clinical Research Delivery (2021) sets out our commitment to create a research positive culture across the National Health Service and to a develop a sustainable and supported research workforce, offering rewarding opportunities and exciting careers for all healthcare and research staff of all professional backgrounds.<\/p><p> <\/p><p>Funding provided through the National Institute for Health and Care Research (NIHR) infrastructure sustains a critical mass of people who are actively involved in conducting and delivering research in the NHS and other health and care settings. This enables clinicians and other health professionals working in the NHS to undertake research, by funding posts or reimbursing NHS trusts for the time their staff are engaged in research. In addition, via the NIHR Clinical Research Network, the NIHR funds front-line research delivery staff who work throughout the NHS and other health and care research settings.<\/p><p> <\/p><p>In August 2023, NIHR also announced £30 million additional funding to support health and care professionals (HCPs) to include research in their careers and help them develop as highly skilled researchers and research leaders. The additional funding will strengthen and expand existing opportunities and introduce new initiatives. This will include new NIHR Regional Research Leadership offices to promote and coordinate research opportunities for HCPs at a regional level.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2023-11-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-11-28T12:44:37.56Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-11-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she is taking steps to encourage NHS Trusts to offer clinical staff the opportunity to work on research trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/415", "label" : {"_value" : "Biography information for Fabian Hamilton"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leeds North East"}
      , "tablingMemberPrinted" : [{"_value" : "Fabian Hamilton"}
      ], "uin" : "3104"}
    , {"_about" : "http://data.parliament.uk/resources/1669432", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1669432/answer", "answerText" : {"_value" : "<p>The Department funds research through the National Institute for Health and Care Research (NIHR). NIHR invests in expertise, specialist facilities, a research delivery workforce and support services to support recruitment to clinical trials. The NIHR Clinical Research Facilities support the delivery of early phase trials and the NIHR Clinical Research Network (CRN) and Patient Recruitment Centres support delivery and participation in later phase clinical trials.<\/p><p>The NIHR also provides the online platform 'Be Part of Research' which allow users to search for and register interest in clinical trials, matching people to trials of relevance to them.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2023-11-16", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-11-16T17:23:48.693Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-11-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help ensure that (a) new clinical trials have the support they need to recruit patients and (b) patients are made aware of clinical trials as a potential way to access new medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1383", "label" : {"_value" : "Biography information for Mark Tami"}
      }
      , "tablingMemberConstituency" : {"_value" : "Alyn and Deeside"}
      , "tablingMemberPrinted" : [{"_value" : "Mark Tami"}
      ], "uin" : "1458"}
    , {"_about" : "http://data.parliament.uk/resources/1668608", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1668608/answer", "answerText" : {"_value" : "<p>The Government will publish a full response to the Lord O\u2019Shaughnessy independent review into commercial clinical trials in autumn 2023.<\/p><p>The response will include an update on progress and implementation of the initial five headline commitments and foundational actions that the Government made in May 2023 as well as all other recommendations in the review.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2023-11-17", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-11-17T12:48:28.67Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-11-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to implement recommendation 27 of Commercial clinical trials in the UK: the Lord O\u2019Shaughnessy review, published on 25 May 2023.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4505", "label" : {"_value" : "Biography information for Peter Kyle"}
      }
      , "tablingMemberConstituency" : {"_value" : "Hove"}
      , "tablingMemberPrinted" : [{"_value" : "Peter Kyle"}
      ], "uin" : "868"}
    , {"_about" : "http://data.parliament.uk/resources/1663689", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1663689/answer", "answerText" : {"_value" : "<p>The Government will publish a full response to the Lord O\u2019Shaughnessy independent review into commercial clinical trials in autumn 2023.<\/p><p>The response will include an update on progress and implementation of the initial five headline commitments and foundational actions that the Government made in May 2023.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-10-17", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "201541"}
        , {"_value" : "201543"}
        , {"_value" : "201544"}
        , {"_value" : "201545"}
        , {"_value" : "201546"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-10-17T11:52:33.27Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-10-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to recommendation 7 of the independent report entitled Commercial clinical trials in the UK: the Lord O\u2019Shaughnessy review - final report, published in May 2023, what plans the Government has to (a) set and (b) meet annual targets for increasing commercial clinical trials in the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4070", "label" : {"_value" : "Biography information for Matt Hancock"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Suffolk"}
      , "tablingMemberPrinted" : [{"_value" : "Matt Hancock"}
      ], "uin" : "201542"}
    , {"_about" : "http://data.parliament.uk/resources/1663690", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1663690/answer", "answerText" : {"_value" : "<p>The Government will publish a full response to the Lord O\u2019Shaughnessy independent review into commercial clinical trials in autumn 2023.<\/p><p>The response will include an update on progress and implementation of the initial five headline commitments and foundational actions that the Government made in May 2023.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-10-17", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "201541"}
        , {"_value" : "201542"}
        , {"_value" : "201544"}
        , {"_value" : "201545"}
        , {"_value" : "201546"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-10-17T11:52:33.3Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-10-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to recommendations 14 and 15 of the independent report entitled Commercial clinical trials in the UK: the Lord O\u2019Shaughnessy review - final report, published in May 2023, what plans the Government has to promote research (a) opportunities and (b) campaigns among clinicians and the public.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4070", "label" : {"_value" : "Biography information for Matt Hancock"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Suffolk"}
      , "tablingMemberPrinted" : [{"_value" : "Matt Hancock"}
      ], "uin" : "201543"}
    , {"_about" : "http://data.parliament.uk/resources/1663692", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1663692/answer", "answerText" : {"_value" : "<p>The Government will publish a full response to the Lord O\u2019Shaughnessy independent review into commercial clinical trials in autumn 2023.<\/p><p>The response will include an update on progress and implementation of the initial five headline commitments and foundational actions that the Government made in May 2023.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-10-17", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "201541"}
        , {"_value" : "201542"}
        , {"_value" : "201543"}
        , {"_value" : "201544"}
        , {"_value" : "201546"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-10-17T11:52:33.427Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-10-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to recommendations 2 and 3 of the independent report entitled Commercial clinical trials in the UK: the Lord O\u2019Shaughnessy review - final report, published in May 2023, whether the Government has taken steps to reduce the (a) regulatory burden of and (b) turnaround time for approving clinical trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4070", "label" : {"_value" : "Biography information for Matt Hancock"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Suffolk"}
      , "tablingMemberPrinted" : [{"_value" : "Matt Hancock"}
      ], "uin" : "201545"}
    , {"_about" : "http://data.parliament.uk/resources/1662007", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1662007/answer", "answerText" : {"_value" : "<p>There is no United Kingdom legislation that mandates animal testing. We do, however, work to a series of International Council of Harmonisation and Committee for Medicinal Products for Human Use guidelines that describe ways to evaluate different non-clinical aspects of medicines, many of which use animals. These aspects include safety pharmacology, repeat dose toxicity, genotoxicity, carcinogenicity, reproductive toxicity, phototoxicity, and immunotoxicity.<\/p><p>The non-clinical assessors have always taken the approach that data from a suitably validated model that has been demonstrated to be predictive could be submitted in lieu of animal data. On a case-by-case basis, a non-clinical assessor will also accept appropriate justifications for not conducting animal tests, for example, no pharmacologically relevant species.<\/p><p>In terms of promoting use of non-animal methods, we do not consider this to be within the remit of non-clinical assessors. Rather, it is for those using these methods to tell the Medicines and Healthcare products Regulatory Agency (MHRA) how they have validated them, or at least why they rely on the results and an assessor will then judge whether the data is appropriate to support the trial. The MHRA supports the developers of products by its offer of scientific advice services, the Innovation Office and the Innovative Licensing and Access Pathway.<\/p><p>The MHRA fully supports the National Centre for the 3Rs (Replacement, Reduction and Refinement), and agency staff play an active role in projects to support adoption and adherence to the 3Rs principles in medicines regulation worldwide.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-10-17", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-10-17T11:41:51.677Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-09-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether it is his Department's policy to authorise novel pharmaceutical products, therapies or medical devices for first-time human clinical trials by the MHRA on a case-by-case basis without relying on a standardised complement of pre-clinical animal toxicity or efficacy data; and what steps he is taking to promote the use of non-animal pre-clinical data.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4677", "label" : {"_value" : "Biography information for Giles Watling"}
      }
      , "tablingMemberConstituency" : {"_value" : "Clacton"}
      , "tablingMemberPrinted" : [{"_value" : "Giles Watling"}
      ], "uin" : "200502"}
    , {"_about" : "http://data.parliament.uk/resources/1652049", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1652049/answer", "answerText" : {"_value" : "<p>On 26 May the Government published its initial response to the Lord O\u2019Shaughnessy review into commercial clinical trials in the United Kingdom. This welcomed all recommendations in principle and made five headline commitments. A fuller response on all the recommendations and an implementation update and longer-term plan will be published in the autumn.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-07-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-07-14T13:45:05.06Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-07-11", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress his Department has made in implementing the recommendations of the Commercial clinical trials in the UK: the Lord O\u2019Shaughnessy review, published 25 May 2023.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"}
      , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"}
      ], "uin" : "193376"}
    , {"_about" : "http://data.parliament.uk/resources/1649373", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1649373/answer", "answerText" : {"_value" : "<p>The Medicines Healthcare products Regulatory Agency (MHRA) is aware that customers who have submitted initial applications and amendments to our Clinical Investigations and Trials team have experienced extended timeframes in some cases and understands how this unpredictability is impacting companies. The MHRA has taken several significant steps to address the extended timeframes for clinical trial approvals. This includes, but is not limited to, prioritising recruitment and training of specialist staff, working with external stakeholders to streamline and improve its processes, and enhancing customer service support and communications. The MHRA regularly reviews and prioritises applications based on public health impact, patient safety and patient need. Unless a human challenge trial application is considered to meet those criteria it is not prioritised over other clinical trial applications.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-07-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-07-05T15:19:28.81Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-06-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps the Medicines and Healthcare products Regulatory Agency is taking to reduce the time it takes to assess human challenge clinical trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4138", "label" : {"_value" : "Biography information for Rushanara Ali"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bethnal Green and Bow"}
      , "tablingMemberPrinted" : [{"_value" : "Rushanara Ali"}
      ], "uin" : "191919"}
    , {"_about" : "http://data.parliament.uk/resources/1649374", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1649374/answer", "answerText" : {"_value" : "<p>The Medicines and Healthcare product Regulatory Agency (MHRA) is dealing with queued applications sequentially. However, the MHRA is reallocating work and routinely evaluates applications for their complexity and prioritises applications based on public health impact, patient safety and patient need. This approach applies to all queued clinical trials including human challenge trial applications that have exceeded the 60-day review deadline.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
        }
        , "answeringMemberConstituency" : {"_value" : "Colchester"}
        , "answeringMemberPrinted" : {"_value" : "Will Quince"}
        , "dateOfAnswer" : {"_value" : "2023-07-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-07-05T15:20:54.26Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-06-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the Medicines and Healthcare products Regulatory Agency expedites human challenge trial applications where a case has gone beyond its 60-day review deadline.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4138", "label" : {"_value" : "Biography information for Rushanara Ali"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bethnal Green and Bow"}
      , "tablingMemberPrinted" : [{"_value" : "Rushanara Ali"}
      ], "uin" : "191920"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&hansardHeading=Clinical+Trials&max-answer.questionFirstAnswered.=2024-01-11T15%3A39%3A08.697Z", "page" : 0, "startIndex" : 1, "totalResults" : 80, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}